Meeting
2015 ASCO Annual Meeting
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Authors
Tara Beth Sanft
Yale Cancer Center, Yale School of Medicine, New Haven, CT
Tara Beth Sanft , Bilge Aktas , Brock Schroeder , Veerle Bossuyt , Michael DiGiovanna , Maysa M. Abu-Khalaf , Gina G. Chung , Andrea Silber , Erin Wysong Hofstatter , Sarah Schellhorn Mougalian , Lianne Epstein , Christos Hatzis , Catherine A. Schnabel , Lajos Pusztai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02057029
Citation
J Clin Oncol 33, 2015 (suppl; abstr 538)
DOI
10.1200/jco.2015.33.15_suppl.538
Abstract #
538
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Predictive testing for selection of patients for extended endocrine therapy: Clinical utilization of Breast Cancer Index (BCI) in early-stage, ER+, LN- breast cancer.
First Author: Stephen C. Malamud
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li
Poster
2022 ASCO Quality Care Symposium
Adjuvant treatment decisions among women age > 65 with early-stage, hormone-receptor breast cancer seen in multidisciplinary clinic versus standard consultation.
First Author: Sara Rachel Alcorn
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden